10.01.05
ReGen Therapeutics Plc, London, U.K., a company whose product Colostrinin has shown efficacy as a potential treatment for Alzheimer’s disease, has been awarded a patent on the use of Colostrinin as an inducer of cytokines. The patent is owned by the Board of Regents of the University of Texas System and is based upon long-term research at the University of Texas Medical Branch (UTMB) at Galveston, which has been sponsored by ReGen. UTMB has licensed the patented technology to ReGen under the worldwide exclusive license agreement that exists between the two parties. The new patent covers the use of Colostrinin, its constituent peptides and analogues to promote cytokine induction. Cytokines are molecules that are involved in communication between cells.
